Duchenne News Tags: Avidity Biosciences

Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1

Avidity announces positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1

April 24, 2023

Avidity announces Fast Track designation to AOC 1044 for the treatment of Duchenne

March 20, 2023

Avidity Biosciences provides an update on the Phase 1/2 MARINA™ trial of AOC 1001 in adults with myotonic dystrophy type 1.

December 14, 2022

Avidity announces positive AOC 1001 date from preliminary MARINA study assessment

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.